1. Generics Bulletin
  2. >>Products
  3. >>Generics

Generic Revlimid Flounders Amid Successful Q2 Performance At Sun

Firm’s US Unit Dropped 9% Sequentially Due To Lack Of Lenalidomide Contributions

 
• By Chloe Kent

Sun delivered an exceptional Q2 performance, marred by a 9% decline in its US business due to a significant drop in lenalidomide sales.

Orange -9% displayed against purple background
Declining sales of generic Revlimid caused a 9% drop to Sun's US business • Source: Shutterstock

Sun Pharmaceutical Industries Ltd. has reported strong growth across its business as it delivered its results for the second quarter of the 2023 financial year, although sales through its US unit fell by 9% sequentially due to a decline in sales of its generic rival to Revlimid (lenalidomide). Q2 revenue was primarily driven by Sun’s branded product portfolio.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.